Related Experiment Video
Updated: Mar 22, 2026
08:22
Isolation of Endocardial and Coronary Endothelial Cells from the Ventricular Free Wall of the Rat Heart
Published on: April 15, 2020
19.7K
Sex-Specific Genetic Variants are Associated With Coronary Endothelial Dysfunction
Satoshi Yoshino1, Rebecca Cilluffo2, Megha Prasad2
1Cardiovascular Medicine and Hypertension, Kagoshima University Hospital, Sakuragaoka, Kagoshima, Japan.
Journal of the American Heart Association
|April 20, 2016
Summary
This study identified specific single-nucleotide polymorphisms (SNPs) linked to coronary endothelial dysfunction. These genetic associations show sex-specific patterns, potentially explaining gender differences in atherosclerosis development.
Area of Science:
- Cardiovascular Genetics
- Atherosclerosis Research
- Molecular Cardiology
Background:
- Endothelial dysfunction is a precursor to atherosclerosis.
- Single-nucleotide polymorphisms (SNPs) are implicated in vascular issues and heart disease.
- Investigating genetic predispositions for endothelial dysfunction is crucial.
Purpose of the Study:
- To identify single-nucleotide polymorphisms (SNPs) associated with coronary endothelial dysfunction.
- To determine if these SNP associations exhibit sex-specific characteristics.
- To explore the role of genetics in gender-related disparities in atherosclerosis.
Main Methods:
- Invasive coronary endothelial function assessment in 643 subjects without obstructive coronary artery disease.
- Analysis of 1536 SNPs previously linked to vascular function, inflammation, and cardiovascular risk.
- Coronary vascular reactivity measured by changes in coronary artery diameter post-acetylcholine injection.
Main Results:
- ADORA1, KCNQ1, and DNAJC4 SNPs were associated with endothelial dysfunction in the overall cohort.
- LPA, MYBPH, ADORA3, and PON1 SNPs showed significant associations in women.
- KIF6 and NFKB1 SNPs were linked to dysfunction specifically in men.
Conclusions:
- Several significant SNPs are associated with an increased risk of coronary endothelial dysfunction.
- The identified SNP associations demonstrate a sex-specific nature.
- These findings may elucidate gender-related differences in the pathogenesis of atherosclerosis.
Related Concept Videos
01:30Coronary Artery Disease I: Introduction
1.6K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.6K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
106
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
106
01:26Coronary Artery Disease II: Pathophysiology
937
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
937
01:29Pharmacogenomics: Identification of New Drug Targets
75
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75
01:27Principles of Pharmacogenetics: Types of Genetic Variants
86
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
86
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
65
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65